Ribeirão Preto School of Medicine, University of São Paulo, 14049-900 Ribeirão Preto, Brazil.
Epilepsy Res. 2011 Mar;94(1-2):117-20. doi: 10.1016/j.eplepsyres.2011.01.007. Epub 2011 Feb 1.
To assess whether levetiracetam elimination is influenced by enzyme inducing antiepileptic drugs (EIAEDs), serum levetiracetam levels were determined at frequent intervals after a single oral 1000mg dose in 15 subjects co-medicated with EIAEDs and 15 matched controls. The EIAED group showed a higher levetiracetam oral clearance (p=0.01) and a shorter half-life (p=0.02) than controls. Although the magnitude of interaction is relatively modest, it could have clinical significance for some patients.
为评估酶诱导型抗癫痫药物(EIAEDs)是否会影响左乙拉西坦的消除,在 15 例合用 EIAEDs 的受试者和 15 例匹配对照者单次口服 1000mg 左乙拉西坦后频繁测定其血清左乙拉西坦水平。EIAED 组的左乙拉西坦口服清除率更高(p=0.01),半衰期更短(p=0.02)。尽管相互作用的幅度相对较小,但对某些患者可能具有临床意义。